Characteristics and trends in macrolide resistance among Helicobacter pylori strains isolated in Bulgaria over four years

被引:16
作者
Boyanova, L
Spassova, Z
Krastev, Z
Petrov, S
Stancheva, I
Docheva, J
Mitov, I
Koumanova, R
机构
[1] Med Univ, Dept Microbiol, Sofia, Bulgaria
[2] Univ Hosp St Ivan Rilski, Dept Gastroenterol, Sofia, Bulgaria
[3] Dist Hosp, Dept Pathol, Sofia, Bulgaria
[4] Hosp Minist Internal Affairs, Dept Gastroenterol, Sofia, Bulgaria
[5] Paediat Univ Hosp, Dept Gastroenterol, Sofia, Bulgaria
关键词
D O I
10.1016/S0732-8893(99)00038-3
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Macrolide resistance trends were examined among Helicobacter pylori strains from 154 patients between 1994 and 1998. Applicabilities of screening agar method (SAM) and modified disk diffusion method (MDDM) were evaluated. Overall primary resistance rates to erythromycin and clarithromycin were 14.8% and 8.7%, respectively. No association was found with age, sex, and diseases. Clarithromycin-resistance rate reached 12.5% in the last 2 years. Secondary resistance to erythromycin occurred more often (in 62.5%) than to clarithromycin (in 42.9%). Therapy with spiramycin or erythromycin in four cases induced no clarithromycin resistance. These data show a considerable prevalence of H. pylori resistance to macrolides, which exhibited a tendency to increase and was often associated with metronidazole resistance. By comparing the MDDM with SAM, an overall agreement was obtained in 81 (94.2%) of 86 results. MDDM and SAM are reliable techniques for testing H. pylori susceptibility to macrolides. (C) 1999 Elsevier Science Inc.
引用
收藏
页码:309 / 313
页数:5
相关论文
共 21 条
[1]   Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin -: Influence on treatment outcome [J].
Adamek, RJ ;
Suerbaum, S ;
Pfaffenbach, B ;
Opferkuch, W .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 1998, 93 (03) :386-389
[2]  
Alarcón T, 1998, J CLIN MICROBIOL, V36, P1165
[3]  
Boyanova L, 1996, EUR J GASTROEN HEPAT, V8, P911
[4]  
DEGROSS AJ, 1993, J CLIN MICROBIOL, V31, P1971
[5]   Variation in erythromycin and clindamycin susceptibilities of Streptococcus pneumoniae by four test methods [J].
Fasola, EI ;
Bajaksouzian, S ;
Appelbaum, PC ;
Jacobs, MR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (01) :129-134
[6]  
GLUPCZYNSKI Y, 1997, CLIN MICROBIOL IN S2, V3, P232
[7]  
GLUPCZYNSKI Y, 1996, HELICOBACTER PYLORI, P17
[8]   TIGHT-BINDING OF CLARITHROMYCIN, ITS 14-(R)-HYDROXY METABOLITE, AND ERYTHROMYCIN TO HELICOBACTER-PYLORI RIBOSOMES [J].
GOLDMAN, RC ;
ZAKULA, D ;
FLAMM, R ;
BEYER, J ;
CAPOBIANCO, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (07) :1496-1500
[9]   Antimicrobial susceptibility testing of 230 Helicobacter pylori strains: Importance of medium, inoculum, and incubation time [J].
Hartzen, SH ;
Andersen, LP ;
Bremmelgaard, A ;
Colding, H ;
Arpi, M ;
Kristiansen, J ;
Justesen, T ;
Espersen, F ;
FrimodtMoller, N ;
Bonnevie, O .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (12) :2634-2639
[10]   EFFECT OF PH VARIATION ON THE SUSCEPTIBILITY OF HELICOBACTER-PYLORI TO 3 MACROLIDE ANTIMICROBIAL AGENTS AND TEMAFLOXACIN [J].
MALANOSKI, GJ ;
ELIOPOULOS, GM ;
FERRARO, MJ ;
MOELLERING, RC .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1993, 12 (02) :131-133